D
David G. Bowen
Researcher at Royal Prince Alfred Hospital
Publications - 172
Citations - 12104
David G. Bowen is an academic researcher from Royal Prince Alfred Hospital. The author has contributed to research in topics: Cytotoxic T cell & T cell. The author has an hindex of 43, co-authored 165 publications receiving 10659 citations. Previous affiliations of David G. Bowen include Centenary Institute of Cancer Medicine and Cell Biology & Bosch.
Papers
More filters
Journal ArticleDOI
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Jyoti Nangalia,Charles E. Massie,E J Baxter,Francesca L. Nice,Gunes Gundem,David C. Wedge,Edward Avezov,Juan Li,Karoline Kollmann,David G. Kent,Athar Aziz,Anna L. Godfrey,Jonathon Hinton,Inigo Martincorena,P Van Loo,Amy V. Jones,Paola Guglielmelli,P. S. Tarpey,Heather P. Harding,J.D. Fitzpatrick,C.T. Goudie,Christina A. Ortmann,Stephen J. Loughran,Keiran Raine,David R. Jones,Adam Butler,Jon W. Teague,Sarah O’Meara,Stuart McLaren,M. Bianchi,Yvonne Silber,D. Dimitropoulou,David Bloxham,L. Mudie,Mark Maddison,Bruce W. S. Robinson,Clodagh Keohane,Cathy MacLean,Kate Hill,Kim Orchard,Sudhir Tauro,Ming-Qing Du,Mel Greaves,David G. Bowen,Brian J. P. Huntly,Claire N. Harrison,Nicholas C.P. Cross,David Ron,Alessandro M. Vannucchi,Elli Papaemmanuil,Peter J. Campbell,Anthony R. Green +51 more
TL;DR: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2, a finding consistent with its role as an initiating mutation in some patients.
Journal ArticleDOI
Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Elli Papaemmanuil,Moritz Gerstung,Luca Malcovati,Sudhir Tauro,Gunes Gundem,Peter Van Loo,Peter Van Loo,Peter Van Loo,Chris J. Yoon,Peter R. Ellis,David C. Wedge,Andrea Pellagatti,Adam Shlien,Michael J. Groves,Simon A. Forbes,Keiran Raine,Jon Hinton,Laura Mudie,Stuart McLaren,Claire Hardy,Calli Latimer,Matteo G. Della Porta,Sarah O’Meara,Ilaria Ambaglio,Anna Gallì,Adam Butler,Gunilla Walldin,Jon W. Teague,Lynn Quek,Alex Sternberg,Alex Sternberg,Carlo Gambacorti-Passerini,Nicholas C.P. Cross,Anthony R. Green,Jacqueline Boultwood,Paresh Vyas,Eva Hellström-Lindberg,David G. Bowen,Mario Cazzola,Michael R. Stratton,Peter J. Campbell,Peter J. Campbell +41 more
TL;DR: Analysis of oncogenic mutations in large, well-characterized cohorts of patients illustrates the interconnections between the cancer genome and disease biology, with considerable potential for clinical application.
Journal ArticleDOI
Adaptive immune responses in acute and chronic hepatitis C virus infection
TL;DR: Key features of adaptive immune responses remain obscure, including mechanisms by which T cells control HCV replication, the role of antibodies in conferring protection and how cellular and humoral immunity are subverted in persistent infection.
Journal ArticleDOI
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
Nicolas Goardon,Emanuele Marchi,Ann Atzberger,Lynn Quek,Anna Schuh,Shamit Soneji,Petter S. Woll,Adam J. Mead,Kate A. Alford,R Rout,Salma Chaudhury,Amanda F. Gilkes,Steven Knapper,Kheira Beldjord,Suriya Begum,Susan Rose,Nicola Geddes,Mike Griffiths,Graham R. Standen,Alexander Sternberg,Jamie Cavenagh,Hannah Hunter,David G. Bowen,Sally Killick,L. G. Robinson,Andrew Price,Elizabeth Macintyre,Paul Virgo,Alan Kenneth Burnett,Charles Craddock,Tariq Enver,Sten Eirik W. Jacobsen,Catherine Porcher,Paresh Vyas +33 more
TL;DR: It is shown that in ∼80% of primary human CD34+ acute myeloid leukemia (AML), two expanded populations with hemopoietic progenitor immunophenotype coexist in most patients, suggesting that in most cases primaryCD34+ AML is a progenitors disease where LSCs acquire abnormal self-renewal potential.
Journal ArticleDOI
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati,Eva Hellström-Lindberg,David G. Bowen,Lionel Ades,Jaroslav Cermak,Consuelo del Cañizo,Matteo G. Della Porta,Pierre Fenaux,Norbert Gattermann,Ulrich Germing,Joop H. Jansen,Moshe Mittelman,Ghulam J. Mufti,Uwe Platzbecker,Guillermo Sanz,Dominik Selleslag,Mette Skov-Holm,Reinhard Stauder,Argiris Symeonidis,Arjan A. van de Loosdrecht,Theo de Witte,Mario Cazzola +21 more
TL;DR: Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program and Guidelines were developed on the basis of a list of patient- and therapy-oriented questions.